The ‘Inflammatory bowel disease (IBD)-Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the IBD, historical and forecasted epidemiology as well as the IBD market trends in the APAC region (Australia, China, India, Japan, and South Korea).
The IBD market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted APAC IBD market size from 2018 to 2030. The Report also covers current IBD treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2018-2030
The inflammation in the digestive tract affects its normal functioning and hampers the nutrient uptake by the body. It is a chronic condition, which means it lasts a long time or constantly comes and goes. There are two kinds of IBD: Crohn’s disease (CD) and Ulcerative colitis (UC). These diseases have many things in common, but there are important differences.
Etrolizumab is being studied in the largest clinical trial program in IBD, comprised of eight randomized-controlled and open-label trials. The landmark study program includes more than 3,100 patients across six Phase III studies, plus two open-label extensions (OLE) and safety monitoring studies for UC, spanning more than 40 countries globally, including head-to-head trials against the most common current treatments.
Different types of immunomodulators, having different modes of action, are being used for the treatment of IBD patients in the APAC market. For years, TNF inhibitors remain the first therapeutics class that has significantly altered UC and CD treatment. However, the use of TNF inhibitors is restricted even in TNF responders due to systemic effects, including immunosuppression and cardiotoxicity, which restrict its use, particularly in elderly individuals. Humira (adalimumab) was one of the best-selling anti-TNF therapies for treating various diseases, including CD and UC, in 2020. It was approved in Japan for the treatment of Crohn’s Disease (CD) in 2010. Amgevita, a biosimilar of Humira, was approved by the Australian Therapeutic Goods Administration in 2017 for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, CD in adults and children (≥6 years), ulcerative colitis, psoriasis in adults and children, hidradenitis suppurativa, and uveitis. Another anti-TNF therapy, infliximab was approved by the Japanese regulatory body in 2002 for the treatment of CD. Later on, this approval was extended for UC also. The 2018 guidelines also included infliximab for the treatment of UC patients in China. In 2018, infliximab biosimilar Inflectra was approved by the Australian regulatory body for the treatment of adult and pediatric Crohn’s disease, refractory fistulising CD, and adult and pediatric UC.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The IBD market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted APAC IBD market size from 2018 to 2030. The Report also covers current IBD treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- Australia
- China
- India
- Japan
- South Korea
Study Period: 2018-2030
Inflammatory bowel disease (IBD) Disease Understanding and Treatment Algorithm
Inflammatory bowel disease (IBD) Overview
The digestive system is one of the largest organ systems in the human body. It starts from the external opening, ‘mouth,’ from where the food is ingested and finishes at the other external opening ‘anus,’ from where the remaining material after the digestion of the food is expelled out of the body. Like any other part of the body, the digestive system and its organs are affected by different ailments, inflammatory bowel disease (IBD) being one of them. Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of any part of the digestive tract. The digestive tract comprises the:
- mouth
- esophagus
- stomach
- small intestine
- large intestine
It is responsible for:
- breaking down food
- extracting nutrients
- removing any unusable material and waste products (Healthline, n.d.)
The inflammation in the digestive tract affects its normal functioning and hampers the nutrient uptake by the body. It is a chronic condition, which means it lasts a long time or constantly comes and goes. There are two kinds of IBD: Crohn’s disease (CD) and Ulcerative colitis (UC). These diseases have many things in common, but there are important differences.
Inflammatory bowel disease (IBD) Diagnosis
A doctor diagnoses IBD in a patient based on different laboratory and imaging tests that includes a combination of endoscopy (for Crohn’s disease) or colonoscopy (for ulcerative colitis) and imaging studies, such as contrast radiography, magnetic resonance imaging (MRI), or computed tomography (CT). Physicians may also check stool samples to ensure symptoms are not caused by an infection or run blood tests to help confirm the diagnosis.Inflammatory bowel disease (IBD) Treatment
IBD is a disease that has no cure. The treatment of IBD aims to relieve symptoms, prevent other problems and future flare-ups, and possibly heal the inflamed intestines. Different treatment approaches are followed for treating an IBD patient. Treatment of IBD involves medications as well as surgery and lifestyle changes.- Medications
Inflammatory bowel disease (IBD) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Number of Prevalent Cases of Inflammatory Bowel Disease (IBD), Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), and Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) scenario in the APAC region (Australia, China, India, Japan, and South Korea) from 2018 to 2030.Key Findings
- Total prevalent population of IBD in the APAC regions was 3,907,112 cases in 2021 which is expected to increase during the study period.
- Japan accounted for third highest (205,859) cases of IBD, compared to other Asian regions (China (1,917,172 cases), India (1,566,102 cases), Australia (168,539 cases), and South Korea (49,440 cases)) in 2021.
- Males accounted for higher number of IBD cases in the APAC region in 2021. There were 1,708,495 cases and 1,293,034 cases of IBD in males and females respectively in 2021.
- The maximum number of prevalent IBD cases in the APAC region were found in the age group 40+ years, followed by those aged 20-39 years. As per estimates, the age group of 40+ years contributed to 1,549,013 cases in 2021, which is anticipated to increase throughout the study period 2018─2030.
- IBD patients are further classified based on the severity of the disease. Patients with mild, and moderate to severe accounts for approximately 1,014,670 cases, and 1,986,860 cases respectively in 2021.
Inflammatory bowel disease (IBD) Epidemiology
The epidemiology segment also provides the IBD epidemiology data and findings across Australia, China, India, Japan, and South Korea.Inflammatory bowel disease (IBD) Drug Chapters
Inflammatory bowel disease (IBD) Marketed DrugsEntyvio (Vedolizumab): Takeda Pharmaceutical
Entyvio (Vedolizumab) is a gut-selective biologic developed by Takeda Pharmaceutical and marketed under the trade name Entyvio. It is a humanized monoclonal antibody designed to specifically antagonize the alpha 4 beta 7 integrin, inhibiting the binding of alpha 4 beta 7 integrins to intestinal Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM-1), but not Vascular Cell Adhesion Molecule 1 (VCAM-1). MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract. The alpha 4 beta 7 integrin is expressed on a subset of circulating white blood cells, and these cells have been shown to play a role in mediating the inflammatory process in UC and CD. By inhibiting alpha 4 beta 7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.Stelara (Ustekinumab): Janssen Pharmaceuticals
Stelara (ustekinumab) is a prescription medicine approved for the treatment of adults 18 years and older with moderately to severely active Crohn’s disease and ulcerative colitis. Many different naturally occurring proteins in the body contribute to inflammation. Patients with Crohn’s disease and ulcerative colitis have elevated levels of two of these proteins, IL-12 and IL-23. Stelara is the only FDA-approved medicine that targets IL-12 and IL-23, which are thought to be associated with gastrointestinal inflammation in Crohn’s disease and Ulcerative Colitis. Stelara is a human IgG1κ monoclonal antibody and is a human interleukin-12 and -23 antagonist.Using DNA recombinant technology, ustekinumab is produced in a murine cell line (Sp2/0). The manufacturing process contains steps for the clearance of viruses. Ustekinumab is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Da.IBD Emerging Drugs
Etrolizumab (RG7413): Hoffmann-La Roche/Genentech
Etrolizumab (RG7413), which Roche and Genentech are developing, is a humanized IgG1 MAb targeting the beta-7 integrin subunit. It is the first dual anti-integrin in trial for IBD. To monitor the trafficking of immune cells in the gut and their inflammatory effects on the intestinal lining, investigators designed etrolizumab to attack IBD on two fronts by binding and selectively inhibiting two integrin receptors, alpha 4 beta 7 and alpha E beta 7. These receptors are required for trafficking and retention in lymphocytes in the gastrointestinal tract and play a role in inflammatory bowel diseases.Etrolizumab is being studied in the largest clinical trial program in IBD, comprised of eight randomized-controlled and open-label trials. The landmark study program includes more than 3,100 patients across six Phase III studies, plus two open-label extensions (OLE) and safety monitoring studies for UC, spanning more than 40 countries globally, including head-to-head trials against the most common current treatments.
Skyrizi (Risankizumab/BI 655066/ABBV-066): AbbVie/Boehringer Ingelheim
Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated by AbbVie and Boehringer Ingelheim. It is investigated to treat multiple inflammatory diseases, including CD and UC. Risankizumab is a humanized monoclonal antibody that targets the p19 subunit of IL-23, which subsequently inhibits the binding of IL-23R and activation of the pro-inflammatory JAK/STAT intracellular signaling pathway. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.Inflammatory bowel disease (IBD) Market Outlook
Inflammatory Bowel Disease (IBD) is a group of gastrointestinal diseases that majorly includes ulcerative colitis (UC) and Crohn’s Disease (CD) with a relapsing-remitting pattern that can affect individuals of all ages. The current treatment landscape of IBD consists of conventional choices such as aminosalicylates, corticosteroids, thiopurines, calcineurin inhibitors, anti-TNF agents, anti-adhesion molecules, and, more recently, small molecules directed against the JAK pathways, anti IL12/23, and cell therapies.Different types of immunomodulators, having different modes of action, are being used for the treatment of IBD patients in the APAC market. For years, TNF inhibitors remain the first therapeutics class that has significantly altered UC and CD treatment. However, the use of TNF inhibitors is restricted even in TNF responders due to systemic effects, including immunosuppression and cardiotoxicity, which restrict its use, particularly in elderly individuals. Humira (adalimumab) was one of the best-selling anti-TNF therapies for treating various diseases, including CD and UC, in 2020. It was approved in Japan for the treatment of Crohn’s Disease (CD) in 2010. Amgevita, a biosimilar of Humira, was approved by the Australian Therapeutic Goods Administration in 2017 for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, CD in adults and children (≥6 years), ulcerative colitis, psoriasis in adults and children, hidradenitis suppurativa, and uveitis. Another anti-TNF therapy, infliximab was approved by the Japanese regulatory body in 2002 for the treatment of CD. Later on, this approval was extended for UC also. The 2018 guidelines also included infliximab for the treatment of UC patients in China. In 2018, infliximab biosimilar Inflectra was approved by the Australian regulatory body for the treatment of adult and pediatric Crohn’s disease, refractory fistulising CD, and adult and pediatric UC.
Key Findings
- The market size of IBD in the APAC region is expected to reach USD 3,672 million by 2030.
- In 2021, China accounts for the highest market size of IBD, compared to the other major markets, i.e., USD 748 million.
- Among the other APAC countries apart from China, Japan had the highest market size with USD 709 million in 2021, while South Korea had the lowest market size of IBD with USD 75 million in 2021.
- Of the emerging therapies Skyrizi, Etrolizumab, Jyselica and others are expected to enter the treatment market, during the forecast period. Alofisel is recently approved in the Japan in 2021 and is expected to enter the other APAC countries.
- The expected launch of potential therapies shall increase the market size in the coming years, assisted by an increase in the prevalent population of IBD during the forecast period (2022-2030).
Australia Market Outlook
This section provides the total IBD market size and; market size by therapies in Australia.China Market Outlook
The total IBD market size and market size by therapies in China is provided in this section.India Market Outlook
In this section, the total IBD market size in India and market size of IBD in Indiaby therapies is provided.Japan Market Outlook
The total IBD market size and market size by therapies in Japan are provided.South Korea Market Outlook
In this section, overall market size and market size by therapies for IBD in South Korea is provided.Inflammatory bowel disease (IBD) Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the IBD market or expected to get launched in the market during the study period 2018-2030. The analysis covers the IBD market uptake by drugs; patient uptake by therapies; and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Inflammatory bowel disease (IBD) Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for IBD emerging therapies.Reimbursement Scenario in Inflammatory bowel disease (IBD)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the IBD market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.Scope of the Report
- The report covers the descriptive overview of IBD, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the IBD epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for IBD is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the IBD market; historical and forecasted is included in the report, covering the APAC drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the APAC IBD market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the IBD market.
- The companies and academics are working to assess challenges and seek opportunities that could influence IBD R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for IBD. The launch of emerging therapies will significantly impact the IBD market.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
IBD Report Insights
- Patient Population
- Therapeutic Approaches
- IBD Pipeline Analysis
- IBD Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
IBD Report Key Strengths
- 9 Years Forecast
- APAC (Australia, China, India, Japan, and South Korea) Coverage
- IBD Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
Drugs Uptake
IBD Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions
Market Insights:
- What was the IBD market share (%) distribution in 2018 and how it would look like in 2030?
- What would be the IBD total market size as well as market size by therapies across the APAC regions during the forecast period (2022-2030)?
- What are the key findings pertaining to the market across the APAC region and which country will have the largest IBD market size during the forecast period (2022-2030)?
- At what CAGR, the IBD market is expected to grow at the APAC level during the forecast period (2022-2030)?
- What would be the IBD market outlook across the APAC region during the forecast period (2022-2030)?
- What would be the IBD market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burdens, and unmet needs of IBD?
- What is the historical IBD patient pool in the APAC region?
- What would be the forecasted patient pool of IBD at the APAC level?
- What will be the growth opportunities across the APAC regions with respect to the patient population pertaining to IBD?
- Out of the above-mentioned countries, which country would have the highest incident population of IBD during the forecast period (2022-2030)?
- At what CAGR the population is expected to grow across the APAC region during the forecast period (2022-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of IBD along with the approved therapy?
- What are the current treatment guidelines for the treatment of IBD in the APAC?
- What are the IBD marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of IBD?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of IBD?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the IBD therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for IBD and their status?
- What are the key designations that have been granted for the emerging therapies for IBD?
- What are the APAC region historical and forecasted market of IBD?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving IBD.
- To understand the future market competition in the IBD market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for IBD in the APAC region (Australia, China, India, Japan, and South Korea).
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the IBD market.
- To understand the future market competition in the IBD market.
Table of Contents
1 Key Insights2 Report Introduction4 Future Prospects5 Executive Summary of Inflammatory Bowel Disease (IBD)6 Key Events9 Patient Journey13 KOL Views14 Market Drivers15 Market Barriers16 SWOT Analysis17 Unmet Needs18 Market Access and Reimbursement20 Capabilities21 Disclaimer22 About the Publisher
3 Inflammatory Bowel Disease (IBD) Market Overview at a Glance
7 Inflammatory bowel disease (IBD): Disease Background and Overview
8 Epidemiology and Patient Population
10 Marketed Therapies
11 Emerging Therapies
12 Inflammatory Bowel Disease (IBD): APAC Market Analysis
19 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Takeda Pharmaceutical
- Janssen Pharmaceuticals
- Pfizer
- Astellas Pharma US
- AstraZeneca
- Tillotts Pharma (Zeria Pharmaceutical)
- Hoffmann-La Roche
- Genentech
- AbbVie
- Boehringer Ingelheim
- Arena Pharmaceuticals
- Eli Lilly and Company
- Kissei Pharmaceutical
- EA Pharma
- Gilead Sciences and Galapagos NV
- Boehringer Ingelheim
- RedHill Biopharma
